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We report 10 heterozygous mutations in the human insulin gene
in 16 probands with neonatal diabetes. A combination of linkage
and a candidate gene approach in a family with four diabetic
members led to the identification of the initial INS gene mutation.
The mutations are inherited in an autosomal dominant manner in
this and two other small families whereas the mutations in the
other 13 patients are de novo. Diabetes presented in probands at
a median age of 9 weeks, usually with diabetic ketoacidosis or
marked hyperglycemia, was not associated with  cell autoanti-
bodies, and was treated from diagnosis with insulin. The mutations
are in critical regions of the preproinsulin molecule, and we predict
that they prevent normal folding and progression of proinsulin in
the insulin secretory pathway. The abnormally folded proinsulin
molecule may induce the unfolded protein response and undergo
degradation in the endoplasmic reticulum, leading to severe en-
doplasmic reticulum stress and potentially  cell death by apopto-
sis. This process has been described in both the Akita and Munich
mouse models that have dominant-acting missense mutations in
the Ins2 gene, leading to loss of  cell function and mass. One of
the human mutations we report here is identical to that in the Akita
mouse. The identification of insulin mutations as a cause of
neonatal diabetes will facilitate the diagnosis and possibly, in time,
treatment of this disorder.
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unfolded protein response
D iabetes mellitus is a heterogeneous group of metabolicdiseases characterized by high blood glucose levels that can
present at any age, from birth to old age. Genetic factors play an
important role in the development of diabetes with some forms
resulting from mutations in a single gene. Although monogenic
forms of diabetes are collectively relatively uncommon, the
identification of the underlying genetic defects has provided
important insights into pancreatic development and the control
of pancreatic  cell function and improvements in diagnosis and
treatment (1–3). Moreover, common variation in the same genes
that can cause monogenic forms of diabetes can affect the risk
of developing the common polygenic forms (4, 5). Neonatal
diabetes (ND), or diabetes developing within the first few weeks
or months of life, is a very rare condition with an incidence of
1 in 400,000 to 500,000 live births (6). Recent studies have shown
that ND can result from abnormalities of an imprinted region of
chromosome 6q24 and mutations in the genes encoding the
glycolytic enzyme, glucokinase, and the two protein subunits
(Kir6.2 and SUR1) of the ATP-sensitive potassium channel of
the pancreatic  cell (2, 7). In addition, mutations in other genes
(IPF1, PTF1A, FOXP3, GLIS3, TCF2, EIF2AK3) can lead to
multisystem diseases that include ND (2). As a result of genetic
studies, the view has emerged that ND is primarily a genetic
disorder and not a congenital form of type 1 diabetes with a
cutoff at around 6 months (8, 9). Spontaneous mutations are
common in ND with 80% of the mutations in KCNJ11 (the gene
encoding Kir6.2) occurring de novo (10). Here, we show that
missense mutations in insulin and its precursors, preproinsulin
and proinsulin, affecting insulin structure and biosynthesis are a
cause of ND. Moreover in 80% of the cases studied to date, they
arose de novo, implicating spontaneous mutations in key pan-
creatic  cell proteins (Kir6.2, SUR1, and insulin) as major
causes of ND.
Results
Identification of Insulin Gene Mutations in ND.During the course of
our studies of ND, we identified a family (UC41; Fig. 1) in which
ND appeared to segregate as a dominant trait. The proband and
other affected family members were screened by direct sequenc-
ing for mutations in KCNJ11 and ABCC8, and none were found.
We were able to obtain DNA samples from several other family
members and carried out a linkage study even though the
maximum expected logarithm of odds (LOD) score was 3.
However, we felt that a search under the peaks could reveal
candidate gene(s).
We identified four regions of the genome that had parametric
LOD scores at or approaching 1.50, the maximum possible LOD
score for the family, assuming autosomal dominant transmission
[supporting information (SI) Fig. 4]. Chromosome 2 had two
adjacent regions of maximum LOD scores at 2q31.2–2q31.3 and
2q32.3–2.33.1: 184.6–187.1 and 191.8–198.1 cM, respectively.
Chromosome 3 had a single region of maximum LOD score at
3q29: 216.5–219.3 cM. Chromosome 6 had three adjacent re-
gions of maximum LOD scores at 6q21, 6q22.1–6q22.31, and
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6q22.31: 109.6–113.6, 118.4–119.8, and 123.7–125.3 cM, respec-
tively. Lastly, chromosome 11 had a single region of maximum
LOD score at 11p15.4: 5.8–8.7 cM. Cataloguing the genes under
each of these linkage peaks led to the identification of NEU-
ROD1 at chromosome 2q31.3, which previously had been im-
plicated as a maturity-onset diabetes of the young (MODY6)
gene (11, 12), and INS at chromosome 11p15 as possible
candidate genes. There were no mutations in the coding region
of NEUROD1. Sequencing of the INS revealed a missense
mutation (G32S) in the codon for residue B8 of the insulin
molecule in the affected family members. This glycine residue is
invariant among insulin sequences and conserved among
insulin-like growth factors. Substitution of GlyB8 with other
L-amino acid residues affects native disulfide pairing, suggesting
that the INS mutation observed in this pedigree was likely to be
pathogenic.
We then sequenced INS in other unrelated patients with ND
without a known genetic cause, collected in Chicago (11 patients
with onset before 6 months of age and 41 patients with onset
between 6 months and 12 months) and Exeter (31 patients with
onset before 6 months of age), and identified nine additional
heterozygous missense mutations in 15 families (Fig. 2 and SI
Table 2), including one individual (ISPAD 157) with the same
mutation (C96Y) found in the Akita mouse (13). Several of the
mutations (A24D, G32S, C43G, F48C, and R89C) were identi-
fied in more than one pedigree, indicating that these positions
could be hot spots for mutations in the insulin gene. Two (G32S
and R89C) of these five recurrent mutations are transitions at a
CpG dinucleotide, hot spots for mammalian mutations. The
mutations are in critical regions of the preproinsulin molecule,
and we predict they prevent normal folding, leading to stimu-
lation of the unfolded protein response (14, 15). All of the
mutations in the A and B chains of insulin affect residues that are
invariant among insulin sequences and also conserved in the
insulin-like growth factors. The mutation R89C affects the site
of proteolytic processing of proinsulin and introduces an addi-
tional exposed cysteine residue at this invariant site among
proinsulin sequences. In the 16 families with an INS mutation
identified to date, the mutation arose de novo in 13 and
cosegregated with diabetes in the other 3 (Fig. 1).
Clinical Characteristics.We identified 10missense mutations in the
INS gene in 21 patients (20 with ND and one with type 2
diabetes) from 16 families (Fig. 1 and SI Table 2). The median
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Fig. 1. Segregation of INS mutations in 16 families. Squares represent male family members, and circles represent female members. Black circles and squares
represent persons with diabetes. A slash mark through the square or circle indicates deceased. A slash mark through the branch indicates the couple has divorced.
The allele status is indicated under the symbols: N/N, two normal alleles; amino acid change/N, one mutated and one normal allele; N/A, not available for testing.
The arrow indicates the proband. Family relationship was confirmed in all families by microsatellite analysis, except in UC2 (parents not available for testing)
and UC105.
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age-at-diagnosis of diabetes in the probands was 9 weeks with
15/16 being diagnosed in the first 6 months. However, three
mutation carriers were diagnosed between 6 months and 1 year,
and in family UC36 with the C43G mutation, the father of the
proband was also a carrier but was surprisingly diagnosed with
mild type 2 diabetes at 30 years of age. Diabetes usually
presented with diabetic ketoacidosis or marked hyperglycemia
(median plasma glucose at diagnosis was 681 mg/dl), was not
associated with  cell autoantibodies and was treated from
diagnosis with insulin usually in replacement doses. C-peptide
values where measured were very low or undetectable, with all
values 200 pmol/liter. All of these features suggest most
patients are insulin-dependent. The median HbA1c was 7.9
(range 5.0 to 9.8), indicating the difficulty in achieving good
glycemic control in insulin-dependent diabetes in infants and
young children.
Birth weight was reduced in keeping with reduced insulin
secretion in utero. The median birth weight was 2,846 g (range
2,115 to 4,026 g), corresponding to the 20th percentile. Inter-
estingly, the pedigrees with patients with later onset of diabetes
(6 months) also had higher birth weights (median 3,392, range
2,892 to 4,026 g), suggesting they had less severe or less rapid
reduction in  cell function in utero and in the first year of life.
We note that three of the patients in the UC41 pedigree were
born to a diabetic mother (the mother of the proband was
diagnosed with diabetes before 2 years of age, she was not
available for genetic testing), which is likely to have increased
their birth weights.
Discussion
We have identified 10 mutations in the insulin gene causing ND.
These mutations differ sharply in their clinical severity from all
of the previously described mutations of this gene in humans.
The earlier described mutations primarily affected the biological
activity of the resultant (pro)insulin molecules but did not impair
their biosynthesis significantly, leading to impaired clearance
accompanied by hyperinsulinemia and hyperproinsulinemia (16,
17). They only resulted in diabetes in the presence of insulin
resistance and in adults. Most carriers were asymptomatic,
although they did exhibit high insulin or proinsulin levels. In
contrast, the mutations identified in patients with ND are severe
enough to cause disruption of the  cells and diabetes early in
life.
Insulin mutations are an important cause of ND. In the large
Exeter permanent ND series they accounted for 38% of cases in
which the genetic etiology was unknown. This finding is 20%
of all permanent ND cases, similar to ABCC8 mutations (19%),
but less than KCNJ11 mutations (30%) (18). KCNJ11 and
ABCC8 mutations also cause transient ND for which the major
cause is abnormalities of imprinting of the ZAC region on
chromosome 6q (19). Clinically, patients with INSmutations are
very similar to those with KCNJ11 and ABCC8mutations except
that they are generally older at diagnosis (Table 1). In this
regard, some of the patients with INS mutations in this series
were diagnosed outside the first 6 months, and further large
series are needed to establish the prevalence of INS mutations
in patients presenting at a wide variety of ages, especially in those
who do not have autoantibodies to islet cell proteins.
Several of the mutations that we report here either disrupt
normal disulfide bonds at B19–A20 (C43G) or A7–B7 (C96Y)
or add an additional unpaired cysteine residue (R89C; G90C) at
the A-chain C-peptide cleavage site, a solvent-exposed position
in the molecule (20). Two other added cysteine mutations lie in
close proximity to the A20–B19 disulfide bond at A19 (Y108C)
and at B24 (F48C) and may cause mispairing of cysteines in this
critical region. The formation of the A20–B19 disulfide bridge
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Fig. 2. Diagram representing the human preproinsulin molecule showing location of mutations causing ND. The amino acid residues in the signal peptide are
indicated in green, the B chain in red, the C-peptide in orange, and the A chain in blue. The dashed circles indicate the basic residues that are the cleavage site
for conversion from proinsulin to insulin. The mutations are noted in black circles together with location in the B or A chain.
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is believed to occur as the first step during folding of the peptide
chain and thus may facilitate subsequent folding steps (21, 22).
All of these mutants are very likely to act in a dominant manner
analogous to the Akita and/or Munich mouse Ins2 mutations to
disrupt insulin biosynthesis and induce endoplasmic reticulum
(ER) stress, i.e., all of these mutants have reactive cysteine
residues that are unpaired. The exact mechanism by which these
unpaired cysteines disrupt ER function remains unclear at this
time (23).
Three other mutations occur at B8 (G32S and G32R) and B23
(G47V) that at first glance do not appear to involve disulfide
bridges. However both glycines are invariant in both insulin and
the insulin-like-growth-factors andmust play an important struc-
tural role because this amino acid uniquely lacks a side chain and
therefore is unlikely to be directly involved in receptor binding.
In the normal insulin T-state conformation, B8 participates in a
 turn at the end of the central B chain -helix that lies adjacent
to the A7–B7 disulfide bond (Fig. 3). Because B8 glycine has a
positive (Phi) dihedral angle (forbidden for L-amino acids), the
presence of L-serine at B8 requires a reorientation of B8
conformation to accommodate its side chain, which results in
rotation of B1–B8, turning the B7 cysteine away from its
intended partner at A7. This change is reflected in lowered
thermodynamic stability of the insulin molecule and significantly
impairs yields in chain recombination experiments (24, 25). On
the basis of these and other observations, Nakagawa et al. (24)
have suggested that ‘‘the correct B8 conformation plays a critical
role in the mechanism of disulfide pairing’’ during insulin
biosynthesis and when substituted may ‘‘kinetically block the
formation of the A7–B7 disulfide bridge.’’ Similar considerations
apply to B23 glycine where L-amino acid substitutions would
likely disrupt normal folding of the peptide chain near the critical
A20–B19 disulfide bridge (26). Therefore, it appears very likely
that these glycine mutations also act similarly to impair proin-
sulin folding and thereby induce ER stress via the unfolded
protein response.
Two of the patients have identical signal peptide cleavage site
mutations that are predicted to inhibit cleavage (Signal P 3.0;
www.signalp.com). Defects in signal peptide cleavage are known
to cause ER stress (27), and similar kinds of mutations have been
described in preprocollagen which decrease expression (28).
Likewise certain preproparathyroid hormone (preproPTH) mu-
tations that impair signal peptide cleavage lead to reduced
secretion with ER retention and rapid degradation accompany-
ing anchoring of preproPTH to the ER membrane (29). One
issue is whether these preproinsulin cleavage mutants have
dominant-negative effects, but they likely would if the proinsulin
is retained in the ER by signal peptide anchoring and/or it
misfolds. The presence of remnants of the signal peptide at its
amino terminus may also impair folding if the signal peptide is
processed within the ER membrane at another site.
It is important to note that one of the mutations we have found
is identical to that of the Akita mouse (13). This finding clearly
establishes the connection between this class of insulin gene
mutations and activation of the unfolded protein response,
leading to inhibition of protein syntheses and eventually  cell
death. Both the Akita and the Munich mice (30) displayed a
more severe phenotype in male than in female mice. This sex
difference is not observed in the patients reported here but
should be kept in mind as more cases of insulin gene mutations
are described in humans.
Studies remain to directly examine the biosynthesis of these
mutant proinsulin molecules to assess their ability to efficiently
fold and be secreted. Furthermore, the possibility exists that
treatments aimed to reduce ER stress might result in improved
 cell survival after differentiation of  cell precursors. This
could partially ameliorate the diabetic state if secretion resulting
from the normal insulin allele could be better preserved.
Glucagon-like peptide-1 receptor agonists and related agents
could be useful in this regard (31, 32).
Materials and Methods
Subjects. Patients from the Chicago group were self-referred or
referred by their local endocrinologist for a genetic evaluation of
ND [11 cases with a diagnosis 6 months of age and 41 with a
diagnosis between 6 and 12 months, negative for KCNJ11 and
ABCC8 mutations (ABCC8 only tested in the latter group in
patients with a birth weight 3,500 g)]. The patients studied at
Peninsula Medical School involved 31 cases with ND diagnosed
before 6 months of age. These patients were selected from the
International Society for Pediatric and Adolescent Diabetes
collection at the PeninsulaMedical School on the basis of normal
sequencing of the coding region of the KCNJ11 and ABCC8
genes, and the availability of parental DNA. They were used in
a previous study of ABCC8 in permanent ND (18). The clinical
and biochemical characteristics of these patients were obtained
by the patients’ local endocrinologists or during a physical
Table 1. Comparison of clinical characteristics of patients with diabetes caused by an INS
mutation, KCNJ11 (8) mutation, or ABCC8 (18) mutation
Characteristic
Molecular genetic etiology
PINS (n  21) KCNJ11 (n  37) ABCC8 (n 16)
Sex, % male 66 62 40 0.16
Age at diagnosis, weeks 13 (4–1,560) 5 (0–26) 7 (0–26) 0.001
Gestational age, weeks 40 (36–41) 39 (32–42) 40 (37–40) 0.3
Birth weight, g 2,846 (2,115–4,026) 2,548 (1,440–3,500) 2,710 (2,200–4,200) 0.4
Centile for birth weight 20 (1–89) 3 (1–58) 12 (1–95) 0.3
Results given in median range are in parentheses.
B
A
A7C
B7C
B8G
A7C
A
B
B7C
B8S
Fig. 3. Predicted effect of the substitution of GlyB8 with Ser on folding of the
insulin molecule. (Left) Normal conformation of the mature insulin molecule
highlighting residues A7, B7, and B8 (shown as space-filling models in both
images). (Right) The effect of substitution at B8 with L-serine, which induces
a major conformational change resulting in reorientation of residues B1–B8,
so as to prevent B7 cysteine from interacting with its intended partner at A7
during folding (see Discussion).
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examination. Percentiles for birth weights were calculated by
using Child Growth Foundation LMS data (33). Age- and
sex-specific percentiles for body mass index were calculated by
using the Centers for Disease Control and Prevention growth
charts (www.cdc.gov).
Linkage Analysis.Four affected and four unaffected familymembers
from the UC41 pedigree (Fig. 1) were genotyped by using the XbaI
chip of theGeneChipHumanMapping 100KChip Set (Affymetrix,
Santa Clara, CA). SNPs were discarded if they did not have
genetic/physical map positions, were monomorphic, or were on the
X orY chromosomes. Geneticmap distances and allele frequencies
were obtained from Affymetrix (www.affymetrix.com/analysis/
downloads/na22/genotyping/Mapping50KXba240.na22.annot.
csv.zip). A total of 41,310 SNPs were available for linkage analysis.
The data were checked for genotyping errors and misspecified
relationships using by PEDCHECK (34) and PLINK (35); addi-
tional 471 SNPs with Mendelian incompatibilities were removed.
From the remaining SNPs, we selected for linkage analysis 8,090
SNPs that were at least 0.2 cM apart and had a 100% call rate in
the eight individuals. Linkage analysis was conducted by using
Allegro 2.0 (36) under a parametric (dominant) genetic model with
disease allele frequency of 0.01% and penetrances 0.0001/0.9999/
0.9999.
Mutation Screening. The human INS gene (37) was amplified in
two segments by using PCR. We used the following primers for
the noncoding exon 1 and the coding exon 2: forward, 5-GGG
TTG AGA GGT AGG GGA GA-3 and reverse, 5-ACA GGG
AGC TGG TCA CTT TT-3. For exon 3, we used the forward
5-AGA GAG CGT GGA GAG AGC TG-3 and the reverse
primer 5- CCC TGA CTG TGT CCT CCT GT-3. We used the
Elongase Amplification System (Invitrogen, Carlsbad, CA). The
PCR conditions were: 94°C 1 min, 35 cycles of 94°C for 30 s, 58°C
for 30 s, and 68°C for 90 s; 68°C for 10 min and 10°C for storage.
We used identical primers for sequencing, and both strands of
the three exons were sequenced by using a 3730xl DNA analyzer
(Applied Biosystems, Foster City, CA). The data analysis was
done with Mutation Surveyor software, version 3.0 (SoftGen-
etics, State College, PA). To confirm family relationships we
used a panel of seven microsatellites on chromosome 20:
D20S107, D20S851, D20S103, D20S477, D20S482, D20S171, and
D20S481.
Proinsulin Folding and Models. Space-filing models of human
insulin showing the predicted effect of G32S (GlyB8) mutation
on structure were generated by using the Insight graphic envi-
ronment software (Biosym Technologies, San Diego).
We thank all of the families and the referring clinicians for their
participation in this study; the International Society for Pediatric and
Adolescent Diabetes (ISPAD), which set up the ISPAD Rare Diabetes
registry; and Dr. S. H. Nakagawa, Dr. C. Ober, Dr. R. Nicolae, Mr. C.
Boustred, Mr. A. Parrish, Ms. L. Hampton, Ms. A. Pastore, and Ms. Z.
Paz for excellent advice and/or technical assistance. Funding for the work
in Exeter was provided by the Wellcome Trust. A.T.H. is a Wellcome
Trust Research Leave Fellow. Funding for the work carried out in
Chicago was provided by Public Health Service Grants DK-13914,
DK-20595, DK-44752, DK-73541, and DK-77489 and by a gift from the
Kovler Family Foundation.
1. Slingerland AS, Hattersley AT (2005) Ann Med 37:186–195.
2. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K (2006) Pediatr
Diabetes 7:352–360.
3. Shield JP (2007) Horm Res 67:77–83.
4. Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E,
Rayner NW, Shields B, Owen KR, Hattersley AT, Frayling TM (2006) PLoS
Med 3:1877–1882.
5. Owen KR, McCarthy MI (2007) Curr Opin Genet Dev 17:239–244.
6. Shield JP, Gardner RJ, Wadsworth EJ, Whiteford ML, James RS, Robinson
DO, Baum JD, Temple IK (1997) Arch Dis Child Fetal Neonatal Ed 76:F39–
F42.
7. Hattersley AT, Pearson ER (2006) Endocrinology 147:2657–2663.
8. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT (2006) Diabe-
tologia 49:1190–1197.
9. Edghill EL, Dix RJ, Flanagan SE, Bingley PJ, Hattersley AT, Ellard S, Gillespie
KM (2006) Diabetes 55:1895–1898.
10. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS,
Howard N, Srinivasan S, Silva JM, Molnes J, et al. (2004) N Engl J Med
350:1838–1849.
11. Malecki MT, Jhala US, Antonellis A, Fields L, Doria A, Orban T, Saad M,
Warram JH, Montminy M, Krolewski AS (1999) Nat Genet 23:323–328.
12. Kristinsson SY, Thorolfsdottir ET, Talseth B, Steingrimsson E, Thorsson AV,
Helgason T, Hreidarsson AB, Arngrimsson R (2001) Diabetologia 44:2098–
2103.
13. Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, Takata K, Koizumi
A, Izumi T (1999) J Clin Invest 103:27–37.
14. Ron D (2002) J Clin Inves 109:443–445.
15. Oyadomari S, Koizumi A, Takeda K, Gotoh T, Akira S, Araki E,MoriM (2002)
J Clin Invest 109:525–532.
16. Tager H, Given B, Baldwin D, Mako M, Markese J, Rubenstein A, Olefsky J,
Kobayashi M, Kolterman O, Poucher R (1979) Nature 281:122–125.
17. Steiner DF, Tager HS, Nanjo K, Chan SJ, Rubenstein AH (1995) in The
Metabolic Basis of Inherited Disease, eds Scriver C, Beaudet A, Sly W, Valle D
(McGraw–Hill, New York), Vol 1, 7th Ed, pp 897–904.
18. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill
EL, Mackay DJG, Proks P, Shimomura K, et al. (2007) Am J Hum Genet
81:375–382.
19. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D,
Shield JP, Temple K, Ellard S, Hattersley AT (2007) Diabetes 56:2178–2182.
20. Lipkind G, Steiner DF (1999) Biochemistry 38:890–896.
21. Qiao ZS, Min CY, Hua QX, Weiss MA, Feng YM (2003) J Biol Chem
278:17800–17809.
22. Hua QX, Mayer JP, Jia W, Zhang J, Weiss MA (2006) J Biol Chem 281:28131–
28142.
23. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T
(2003) Diabetes 52:409–416.
24. Nakagawa SH, Zhao M, Hua QX, Hu SQ, Wan ZL, Jia W, Weiss MA (2005)
Biochemistry 44:4984–4999.
25. Hua QX, Nakagawa S, Hu SQ, Jia W, Wang S, Weiss MA (2006) J Biol Chem
281:24900–24909.
26. Nakagawa SH, Hua QX, Hu SQ, Jia W, Wang S, Katsoyannis PG, Weiss MA
(2006) J Biol Chem 281:22386–22396.
27. Green N, Fang H, Miles S, Lively MO (2001) in Cotranslational and Posttrans-
lational Proteolysis of Proteins, eds Dalbey RE, Sigman DS (Academic, San
Diego), Vol XXII, pp 58–76.
28. Favor J, Gloeckner CJ, Janik D, Klempt M, Neuhauser-Klaus A, Pretsch W,
Schmahl W, Quintanilla-Fend L (2007) Genetics 175:725–736.
29. Arnold A, Horst SA, Gardella TJ, BabaH, LevineMA, KronenbergHM (1990)
J Clin Invest 86:1084–1087.
30. Herbach N, Rathkolb B, Kemter E, Pichl L, KlaftenM, de Angelis MH, Halban
PA, Wolf E, Aigner B, Wanke R (2007) Diabetes 56:1268–1276.
31. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D,
Ling Z, Drucker DJ (2006) Cell Metab 4:391–406.
32. Wek RC, Anthony TG (2006) Cell Metab 4:333–334.
33. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA (1995) Arch
Dis Child 73:17–24.
34. O’Connell JR, Weeks DE (1998) Am J Hum Genet 63:259–266.
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D,
Maller J, de Bakker PIW, Daly MJ, Sham PC (2007) Am J Hum Genet
81:559–579.
36. Gudbjartsson DF, Jonasson K, Frigge ML, Kong A (2000) Nat Genet 25:12–13.
37. Bell GI, Pictet RL, Rutter WJ, Cordell B, Tischer E, Goodman HM (1980)
Nature 284:26–32.
15044  www.pnas.orgcgidoi10.1073pnas.0707291104 Støy et al.

